25867-86-1

Upstream product

• 25867-84-9 C₁₂H₁₀Br₂O₃ 

Downstream Products

• 37794-26-6 1,4-dibromopentacyclo<4.3.0.0^2,50^3,80^4,7>nonan-9-one ethylene ketal 
• 33145-38-9 4-Chloro-1-bromopentacyclo<4.3.0.0^2,5.0^3,8.0^4,7>nonan-9-one ethylene acetal 
• 124964-79-0 4-Tosyloxy-1-bromopentacyclo<4.3.0.0^2,5.0^3,8.0^4,7>nonan-9-one ethylene acetal 
• 37794-26-6 1,4-Dibromopentacyclo<4.3.0.0^2,5.0^3,8.0^4,7>nonan-9-one Ethylene Ketal 
• 119045-19-1 4-amino-1-bromopentacyclo<4.3.0.0^2,5.0^3,8.0^4,7>nonan-9-one ethylene acetal 
• 41100-10-1 1-bromopentacyclo(4.3.0.0^2.5.0^3.8.0^4.7)nonan-9-one ethylene ketal 4-diphenylcarbinol 

Relevant academic research and scientific papers

Preparation and testing of homocubyl amines as therapeutic NMDA receptor antagonists

Computational modeling demonstrates that the van-der-Waals surfaces of homocubyl amines are similar to that of the neuroprotector Memantine . Utilizing readily available precursors we report the preparation of a series of homological cubylamines, namely pentacyclo[6.3.0. 02,6.03,10.05,9]undecyl-4-amine (trishomocubyl-4-amine, 2), pentacyclo[5.3.0.02,5.0 3,9.04,8]decyl-10-amine (bishomocubyl-10-amine, 3), pentacyclo[4.3.0.02,5.03,8.04,7]nonyl-9-amine (homocubyl-9-amine, 4), and pentacyclo[4.2.0.02,5.0 3,8.04,7]octyl-1-amine (cubylamine, 5). The hydrochlorides of amines 2-5 show pronounced affinity for the (+)MK-801 channel binding site, and it seems likely that these compounds would act as very fast voltage-dependent NMDA receptor antagonists.